Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 03, 2023 10:46 ET | Travere Therapeutics, Inc.
“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine
June 08, 2023 00:20 ET | Burning Rock Biotech Limited
GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
February 23, 2023 08:05 ET | uniQure Inc.
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for...
Intermountain Healthcare Logo
Intermountain Healthcare Researchers Play Key Role in New Study Finding Antiviral Drug is Effective in Preventing Severe Illness in COVID Patients When Given Early
December 22, 2021 17:48 ET | Intermountain Healthcare
Salt Lake City, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Researchers from Intermountain Healthcare played a key role in a new international study that has found that an antiviral drug designed to inhibit...
In Vitro Study Publi
In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations
February 17, 2021 17:13 ET | BioNTech SE
New York, NY and Mainz, Germany, February 17, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study that provides additional...
Im The New England J
Im The New England Journal of Medicine veröffentlichte in-vitro-Daten zeigen, dass Seren von mit dem Pfizer-BioNTech COVID-19-Impfstoff geimpften Personen SARS-CoV-2 mit der Südafrika-Spike-Mutation neutralisieren
February 17, 2021 17:13 ET | BioNTech SE
New York, USA und Mainz, DEUTSCHLAND, 17. Februar 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute Ergebnisse einer in-vitro-Studie bekannt, die zusätzliche...
The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
July 08, 2020 17:01 ET | Biogen Inc.
Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal...
The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis
July 24, 2019 18:53 ET | FibroGen, Inc
-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine -- SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN)...
Largest Study of Its Kind Uses AI to Identify Unmet Needs of Patients with Severe Chronic Conditions; Emotional Support Takes Top Spot
January 30, 2019 15:00 ET | ARTIS Ventures
San Francisco, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Today, NEJM Catalyst published new research co-authored by healthcare executives from UCB, ARTIS Ventures and Quid, that analyzed more than 500,000...
Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results
January 12, 2017 08:05 ET | Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...